WebTegatrabetan (BC-2059, BC2059, Tegavivint) is an orally bioavailable ?-catenin antagonist. Target : Beta-catenin. CAS Number : 1227637-23-1. Formula Weight : 588.74 WebMar 3, 2024 · This phase Ib trial is to find out the best dose, possible benefits and/or side effects of osimertinib and tegavivint as first-line therapy in treating patients with EGFR-mutant non-small cell lung cancer that has spread to other places in the body (metastatic).

Tegatrabetan (BC-2059) ≥99% (HPLC) Selleck Wnt/beta …

WebTegatrabetan (BC2059) is a β-Catenin antagonist. Tegatrabetan disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1). Buy Wnt/beta-catenin … WebCompare Tegatrabetan from Biorbyt on Biocompare.com. Specifications/Features Application Notes: Tegatrabetan (BC-2059, BC2059, Tegavivint) is an orally bioavailable β-catenin antagonist that disrupts the binding of β-catenin to TBL1 and promotes β-catenin degradation, attenuates nuclear and cytoplasmic levels of β-catenin. dramatic irony in an inspector calls

Tegatrabetan MedChemExpress Life Science Reagents

WebTegatrabetan (BC2059) is a β-Catenin antagonist. Tegatrabetan disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1)[1]. CAS Number: 1227637-23-1 WebIn Vivo Tegatrabetan (BC2059; 1.0 or 5.0 mg/kg/day; intravenously) significantly improves the median survival of the mice from approximately 17.5 to 39 days. Treatment with … WebIn Vivo Tegatrabetan (BC2059; 1.0 or 5.0 mg/kg/day; intravenously) significantly improves the median survival of the mice from approximately 17.5 to 39 days. Treatment with Tegatrabetan (10 mg/kg/day; intravenously) alone further improves the median survival to 51.5 days[1]. MCE has not independently confirmed the accuracy of these methods. emotional health books for children